silicon gasket. The findings support a manufacturerelated cause over a patient-or surgical-related cause for opacification. Although no conclusions can be drawn about the nature of this unknown aetiological factor, our data pinpoint it within a narrow time frame of manufacture.
Eye (2010) 24, 1627-1628; doi:10.1038/eye.2010.97; published online 9 July 2010 Sir, Effect of lyophilization on the in vitro biological activity of bevacizumab Intravitreal bevacizumab has been effective for vascular endothelial growth factor (VEGF)-mediated diseases of the retina and choroids. 1, 2, 3 However, repeated injections may be required. An alternative mode of administration would be a biodegradable intravitreal implant 4 of lyophilized bevacizumab, which has not been previously reported.
In an effort to assess the viability of a biodegradable intravitreal implant of lyophilized bevacizumab, we a The total number includes one lens of which the opacity could not be assessed and also another lens of which serial number was unknown.
evaluated the effect of the lyophilization process of bevacizumab solution on the in vitro binding activity of bevacizumab to VEGF 165 . The commercial solution of bevacizumab (Avastin 100 mg/4 ml; Genentech Inc., South San Francisco, CA, USA) was frozen at À40 1C for 24 h and then lyophilized (E-C Modulyo; E-C Apparatus Inc., New York, NY, USA). It was then stored in dry bottles in a low moist environment. The lyophilized bevacizumab was diluted in Tris-buffered saline at 1 mg/ml and used in western blot analysis.
The VEGF 165 (Sigma-Aldrich, St Louis, MO, USA) was transferred to nitrocellulose membranes (Transblot 0.45 mM; Bio-Rad Laboratories, Richmond, CA, USA) after denaturation. The blot was blocked by 5% skim milk in Tris-buffered saline with 0.05% Tween (TTBS) for 1 h at room temperature and incubated overnight at 4 1C with primary antibody against VEGF or bevacizumab (Avastin lyophilized) at 1 : 2500 dilution. After washing with TTBS, we incubated blots with peroxidase-conjugated goat anti-human secondary antibody for 30 min at room temperature. After the final wash, we incubated the blot with chemiluminescence reagent (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and the signal was detected with Amersham film (Hyperfilm; GE Healthcare, Little Chalfont, Buckinghamshire, UK).
Gel electrophoresis confirmed the migration pattern of VEGF 165 (Figure 1a) . Subsequently, western blot analysis showed that bevacizumab could still bind to VEGF 165 in vitro. A positive immunoreaction of bevacizumab with VEGF 165 was revealed by a chemiluminescent reaction (Figure 1b) .
This study shows that bevacizumab is still active after freezing and lyophilization, which are essential steps in the development of a biodegradable intravitreal implant. Even deep freezing did not alter the binding activity of bevacizumab to VEGF 165 , which was a concern. 5 Upcoming in vivo studies on chick embryos will allow us to definitely test the bioactivity of bevacizumab biodegradable intravitreal implants.
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